Joel Beatty
Stock Analyst at Baird
(4.16)
# 462
Out of 4,876 analysts
202
Total ratings
42.59%
Success rate
16.82%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Neutral | $7 → $9 | $9.14 | -1.53% | 5 | Jun 20, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $110 → $145 | $126.33 | +14.78% | 6 | Jun 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $22.12 | +40.14% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $16.21 | +48.06% | 3 | May 16, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $8 → $4 | $2.28 | +75.44% | 4 | May 13, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $58 → $50 | $17.66 | +183.13% | 2 | May 13, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $560.14 | +21.40% | 7 | May 13, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $29 | $14.10 | +105.75% | 2 | May 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $70 → $66 | $49.81 | +32.50% | 15 | May 7, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $167 → $155 | $106.90 | +45.00% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $7.10 | -1.41% | 5 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $103.39 | +56.69% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $28.81 | +42.31% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $10 | $3.03 | +230.03% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $6.55 | +144.27% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $4.12 | +288.35% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $43.00 | +69.77% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $21.78 | +46.92% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $23.27 | +222.30% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $6.33 | +73.78% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.65 | +324.24% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $55.18 | +17.80% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $127 | $128.11 | -0.87% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $36.52 | +97.15% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $20 | $0.22 | +8,840.55% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.48 | +204.05% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $11.64 | +114.78% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.26 | +3,340.37% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $9.03 | +210.25% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $5.33 | +200.19% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $2.51 | -50.20% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.25 | +3,420.00% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $16.08 | +260.70% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $21.37 | +12.31% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $13.30 | +35.39% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $3.15 | +90.48% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $1.08 | +2,770.37% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $5.16 | +442.64% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $322.83 | -45.79% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.78 | +192.89% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $17.11 | +531.21% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $39.80 | +95.98% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $8.88 | +1,026.13% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $15.71 | +663.84% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $1.83 | +24,490.16% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $0.99 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $6.37 | +135.48% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.60 | +19,933.39% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $5.67 | +235.10% | 3 | Nov 10, 2017 |
Sage Therapeutics
Jun 20, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $9.14
Upside: -1.53%
e.l.f. Beauty
Jun 6, 2025
Maintains: Outperform
Price Target: $110 → $145
Current: $126.33
Upside: +14.78%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $22.12
Upside: +40.14%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $16.21
Upside: +48.06%
Editas Medicine
May 13, 2025
Maintains: Outperform
Price Target: $8 → $4
Current: $2.28
Upside: +75.44%
Dianthus Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $58 → $50
Current: $17.66
Upside: +183.13%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $560.14
Upside: +21.40%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $14.10
Upside: +105.75%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $49.81
Upside: +32.50%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $167 → $155
Current: $106.90
Upside: +45.00%
May 7, 2025
Maintains: Neutral
Price Target: $8 → $7
Current: $7.10
Upside: -1.41%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $103.39
Upside: +56.69%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $28.81
Upside: +42.31%
Mar 25, 2025
Maintains: Outperform
Price Target: $13 → $10
Current: $3.03
Upside: +230.03%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $6.55
Upside: +144.27%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $4.12
Upside: +288.35%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $43.00
Upside: +69.77%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $21.78
Upside: +46.92%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $23.27
Upside: +222.30%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $6.33
Upside: +73.78%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.65
Upside: +324.24%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $55.18
Upside: +17.80%
Aug 2, 2024
Maintains: Outperform
Price Target: $112 → $127
Current: $128.11
Upside: -0.87%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $36.52
Upside: +97.15%
May 15, 2024
Maintains: Outperform
Price Target: $45 → $20
Current: $0.22
Upside: +8,840.55%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.48
Upside: +204.05%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $11.64
Upside: +114.78%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.26
Upside: +3,340.37%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $9.03
Upside: +210.25%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $5.33
Upside: +200.19%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $2.51
Upside: -50.20%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.25
Upside: +3,420.00%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $16.08
Upside: +260.70%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $21.37
Upside: +12.31%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $13.30
Upside: +35.39%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $3.15
Upside: +90.48%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $1.08
Upside: +2,770.37%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $5.16
Upside: +442.64%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $322.83
Upside: -45.79%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.78
Upside: +192.89%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $17.11
Upside: +531.21%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $39.80
Upside: +95.98%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $8.88
Upside: +1,026.13%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $15.71
Upside: +663.84%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $1.83
Upside: +24,490.16%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $0.99
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $6.37
Upside: +135.48%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.60
Upside: +19,933.39%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $5.67
Upside: +235.10%